Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 42 of 147 for:    visilizumab

AbATE Follow-Up Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02067923
Recruitment Status : Completed
First Posted : February 20, 2014
Last Update Posted : January 17, 2018
Sponsor:
Information provided by (Responsible Party):
Yale University

Brief Summary:

This study proposes to conduct a non-interventional, multi-center trial that will look at C-peptide results from one or two Mixed Meal Tolerance Tests (MMTT) in participants who received anti-CD3 treatment or placebo on the Abate ITN027AI trial. Anti-CD3 monoclonal antibody is a humanized antibody that is commonly used to prevent organ rejection. It was give in order to determine whether anti-CD3 mAb treatment can halt the progression of newly diagnosed type 1 diabetes.

The overall hypothesis of this study is there will be less change in c-peptide levels of the previously treated group versus the control group.


Condition or disease
Diabetes Mellitus, Type 1

Detailed Description:

We propose to conduct a non-interventional multi-center trial that will look at C-peptide results from one or two Mixed Meal Tolerance Tests (MMTT) in participants who received anti-CD3 treatment or placebo on the Abate ITN027AI trial. The first few subjects went on the trial late in 2005 and the last subjects were enrolled in 2009.The mixed meal tolerance tests will coincide with approximately 4 years and 6 years post ITN027AI study completion for each participant. Those participants, who completed the ITN027AI study in 2007 and 2008, will only have a single MMTT.

We plan to enroll approximately 77 subjects at 5 sites who were previously active with ITN027AI.. Both the drug treated and the control group participants will be invited to participate. Along with Yale University these sites include, the University of California-San Francisco, University of Colorado-Barbara Davis, Benaroya Research Institute, and Pacific Northwest Research Institute -University of Washington. The investigators of each of these sites will be asked to contact their patients who were originally on the ITN027AI study.

Subjects will be contacted via email or phone to see if they would be interested in participating on this Abate follow-up study. Eligible participants will come to the Yale University Church St. Research Unit or other participating ITN study site for either 1 or 2 mixed meal tolerance tests to determine their current c-peptide status. The available sites for participants to go to include: Yale University, University of California-San Francisco, University of Colorado-Barbara Davis Center, Benaroya Research Institute and Pacific Northwest-University of Washington.

This first visit will consist of the following: an explanation of the study, an assessment of inclusion/exclusion criteria and documentation of informed consent. If the subject meets the inclusion/exclusion criteria, a complete medical history will be obtained, physical examination including vital signs, urine pregnancy test if a female of childbearing potential and an assessment of concomitant medications. The subject will then have a Mixed Meal Tolerance Tests (MMTT) with a possible 2nd MMTT with C-Peptide and glucose measurements a year later based on how long it has been since they were on the ITN027AI Study.The subject will also have a 4 hour urine collection for C-peptide and creatinine during this MMTT. If a repeat MMTT is done a year later then another 4 hour urine sample during the MMTT will be collected for C-peptide and Creatinine measurement.


Layout table for study information
Study Type : Observational
Actual Enrollment : 44 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: ITN0127AI Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (AbATE) Follow-Up Study
Actual Study Start Date : February 2014
Actual Primary Completion Date : January 2016
Actual Study Completion Date : November 17, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Group/Cohort
Anti-CD3 mAb Plus Diabetes Standard of Care Group
This group of individuals received treatment in the original AbATE study.
Diabetes Standard of Care Group
During the original AbATE study these individuals received standard care.



Primary Outcome Measures :
  1. Mixed Meal Tolerance Test (MMTT) C-peptide levels [ Time Frame: 1 Study Day ]
    Labs will be obtained to assess beta cell function via c-peptide levels and glucose at 11 time points during the mixed meal tolerance test. Blood samples will be obtained prior to the start of the mixed meal tolerance test to assess auto-antibody status and HbA1c. Approximately 60 cc's of blood will also be obtained for PBMC's and future studies as related to the immunology and genetics of T1DM. A 4 hour urine sample during the MMTT will be collected for C-peptide and Creatinine measurement. We plan to determine the relationship between this measurement and the insulin secretory response.


Secondary Outcome Measures :
  1. Safety experience [ Time Frame: 1 Study Day ]
    To determine the safety experience and diabetes specific clinical parameters in previous participants in the ITN027 trial via the history of hospitalizations and other adverse events since the participants came of the original ITN027AI Treatment Trial.


Biospecimen Retention:   Samples With DNA
blood urine


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 37 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The investigators will contact their patients who were originally on the ITN027AI (AbATE) study. Subjects will be contacted via email or phone to see if they would be interested in participating on this Abate follow-up study.
Criteria

Inclusion Criteria:

  • Prior participation on either the treatment or the control arm of the Abate ITN027AI trial
  • Signed Informed Consent

Exclusion Criteria:

  • Inability or unwillingness to give informed consent
  • Participation in an investigational treatment trial within the last 6 weeks before enrollment
  • Ongoing major systemic illness.
  • Clinically active serious infections.
  • Any medical condition that in the opinion of the investigator would interfere with safe completion of the trial.
  • Positive pregnancy test in menstruating women
  • Actively breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02067923


Locations
Layout table for location information
United States, Connecticut
Church Street Research Unit
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
Investigators
Layout table for investigator information
Principal Investigator: Kevan Herold, MD Yale University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT02067923     History of Changes
Other Study ID Numbers: 1310012954
First Posted: February 20, 2014    Key Record Dates
Last Update Posted: January 17, 2018
Last Verified: January 2018
Keywords provided by Yale University:
T1D
type 1 diabetes
type 1 diabetes mellitus
juvenile diabetes
autoimmune diabetes
autoimmune
anti-CD3 mAb
mAb hOKT3g1(Ala-Ala)
teplizumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases